Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.
For media inquiries, contact
Vice President for Communications
Dietary supplement could improve treatment of some blood cancers
Ludwig Lausanne researchers and colleagues show that a vitamin B3 analogue, nicotinamide riboside, boosts the stem cells that make blood in an animal model
March 7, 2019, New York — A study led by Nicola Vannini of Ludwig Cancer Research and Olaia Naveiras of the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland has found that dietary supplementation with nicotinamide riboside, an analogue of vitamin B3, dramatically boosts the production of blood cells by hematopoietic stem cells (HSCs) in mice. This finding has the potential to significantly reduce the toxicity of chemotherapy in stem cell-based therapies for the treatment of leukemia and aggressive lymphomas if it translates to humans.
In such cases, the patient’s cancerous blood stem cells are removed and, if necessary, replaced with healthy ones from a donor. However, up to a quarter of cases end in death, often because blood cells are not replenished fast enough to prevent infections.
HSCs slow down in patients due to stress, which increases the activity of mitochondria, the energy-generating organelles of the cell: To meet the high demand of rebuilding blood cells, mitochondria in HSCs ramp up a process that generates fuel for the cell. But this also ages HSCs prematurely, causing the observed dysfunction.
The research team—which included many other scientists at the Lausanne branch of the Ludwig Institute for Cancer Research, EPFL and the University Hospital of Lausanne (CHUV)—reports in the current issue of Cell Stem Cell that exposing human and mouse HSCs to an analogue of vitamin B3, nicotinamide riboside, boosts their function, ability to replace stressed-out mitochondria and to divide.
Fed to mice subjected to an irradiation procedure that eliminated their blood cells, the supplement improved their survival by 80% and accelerated blood recovery. In immunodeficient mice, it increased the production of immune cells. This is the first study to show that nicotinamide riboside as a dietary supplement has the potential to significantly ameliorate blood-recovery problems in cancer patients, even after chemo- or radio-therapy.
The EPFL release from which this summary is derived can be found here.